Daily Stock Analysis, CPRX, Catalyst Pharmaceuticals Inc, priceseries

Catalyst Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
2.42
Close
2.40
High
2.52
Low
2.40
Previous Close
2.44
Daily Price Gain
-0.04
YTD High
3.20
YTD High Date
Jul 27, 2017
YTD Low
1.02
YTD Low Date
Jan 3, 2017
YTD Price Change
1.27
YTD Gain
112.39%
52 Week High
3.20
52 Week High Date
Jul 27, 2017
52 Week Low
0.94
52 Week Low Date
Oct 28, 2016
52 Week Price Change
1.23
52 Week Gain
105.13%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 23. 2015
3.06
Feb 4. 2015
3.26
8 Trading Days
6.60%
Link
LONG
Mar 4. 2015
3.75
Mar 23. 2015
4.40
13 Trading Days
17.47%
Link
LONG
Mar 31. 2015
4.33
Apr 15. 2015
4.59
10 Trading Days
6.02%
Link
LONG
Jun 30. 2015
4.13
Jul 27. 2015
5.13
18 Trading Days
24.13%
Link
LONG
Mar 21. 2016
1.23
Mar 23. 2016
1.31
2 Trading Days
6.50%
Link
LONG
Sep 19. 2016
1.03
Sep 29. 2016
1.12
8 Trading Days
8.97%
Link
LONG
Mar 13. 2017
1.14
Apr 4. 2017
1.78
16 Trading Days
55.71%
Link
LONG
Jun 19. 2017
2.39
Jul 13. 2017
2.74
17 Trading Days
14.84%
Link
Company Information
Stock Symbol
CPRX
Exchange
NasdaqCM
Company URL
http://www.catalystpharma.com
Company Phone
(305) 529-2522
CEO
Patrick J. McEnany
Headquarters
Florida
Business Address
355 ALHAMBRA CIRCLE, SUITE 1250, CORAL GABLES, FL 33134
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001369568
About

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder. The company was founded by McEnany J. Patrick and Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.

Description

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. Its lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which completed Phase III clinical trial for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of MuSK-antibody positive myasthenia gravis. The company also develops CPP-115, a GABA aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy and other neurological indications, such as complex partial seizures and Tourette's disorder; and CPP-109 to treat Tourette's disorder. It has a strategic collaboration with BioMarin Pharmaceutical Inc. for the development of Firdapse. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.